Tolerability and Safety of the New Anti-Obesity Medications

Drug Safety

Volumn 37, Issue 9, 2014, Pages 693-702

  Hainer, Vojtech ^a   Aldhoon Hainerová, Irena ^a,b  

^a INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIOBESITY AGENT; BENZAZEPINE DERIVATIVE; BENZOXAZINE DERIVATIVE; CETILISTAT; FRUCTOSE; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; LORCASERIN; NALTREXONE; PHENTERMINE; TOPIRAMATE;

ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; HUMAN; MEDICINAL CHEMISTRY; OBESITY;

ANTI-OBESITY AGENTS; BENZAZEPINES; BENZOXAZINES; BUPROPION; CHEMISTRY, PHARMACEUTICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FRUCTOSE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; NALTREXONE; OBESITY; PHENTERMINE;

EID: 84929044754     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0206-3     Document Type: Review

References (57)

1. World Health Organization. Media centre. Obesity and overweight. Fact sheet no. 311, updated March 2013. http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed 21 July 2014
2. World Health Organization. Obesity: preventing and managing the global epidemic: report of a WHO consultation (WHO Technical Report Series 894). Geneva: WHO Consultation on Obesity; 2000. pp. 1–153
3. Tsigos C, Hainer V, Basdevant A, et al. Obesity Management Task Force of the European Association for the Study of Obesity. Management of obesity in adults: European clinical practice guidelines. Obes Facts. 2008;1:106–16.
4. Fried M, Yumuk V, Oppert JM, et al. Interdisciplinary European guidelines on metabolic and bariatric surgery. Obes Facts. 2013;6:449–68.
5. Freemark M. Pharmacotherapy of childhood obesity: an evidence-based, conceptual approach. Diabetes Care. 2007;30:395–402.
6. Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–54.
7. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring). 2014;22:5–13.
8. Gardin JM, Schumacher D, Constantine G, et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA. 2000;283:1703–9.
9. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370:1706–13.
10. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905–17.
11. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–61.
12. Hainer V, Aldhoon Hainerová I. Do we need anti-obesity drugs? Diabetes Metab Res Rev. 2012;28(Suppl 2):8–20.
13. Colman E, Golden J, Roberts M, et al. The FDA’s assessment of two drugs for chronic weight management. N Engl J Med. 2012;367:1577–9.
14. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2011;20:330–42.
15. Gadde KM, Allison DB, Ryan DH, et al. Effect of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-contolled, phase 3 trial. Lancet. 2011;377:1341–52.
16. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308.
17. Smith SR, Weissman NJ, Anderson CM, Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–56.
18. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067–77.
19. O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the Bloom-DM study. Obesity (Silver Spring). 2012;20:1426–36.
20. Rider JA, Moeller HC. Double-blind evaluation of the use of phentermine in treating obesity. Appl Ther. 1963;5:523–4.
21. Block JP, Choudhry NK, Carpenter DP, et al. Time series analyses of the effect of FDA communications on use of prescription weight loss medications. Obesity (Silver Spring). 2014;22:943–9.
22. Ben-Menachem E, Henriksen O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia. 1996;37:539–43.
23. 2C receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab. 2011;96:837–45.
24. Aronne LJ, Wadden TA, Peterson C, et al. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013;21:2163–71.
25. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. 1992;16:397–415.
26. Winslow DH, Bowden CH, DiDonato KP, et al. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep. 2012;35:1529–39.
27. Garvey WT, Ryan DH, Henry R, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended-release. Diabetes Care. 2014;37:912–21.
28. 2. Am J Cardiol. 2013;111:1131–8.
29. Bays H. Phetermine, topiramate and their combination for the treatment of adiposopathy (‘sick fat’) and metabolic disease. Expert Rev Cardiovasc Ther. 2010;8:1777–81.
30. Adipex-P (phentermine) prescribing information. Philadelphia: Teva Pharmaceuticals USA, Inc.; 2012.
31. Hendricks EJ, Greenway FL, Westman EC, et al. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Sliver Spring). 2011;19:2351–60.
32. TM) combination for the treatment of obesity. Diabetes Metab Syndr Obes. 2013;6:131–9.
33. Jordan J, Astrup A, Engeli S, et al. Cardiovascular effects of phentemine and topiramate: a new drug combination for the treatment of obesity. J Hypertens. 2014;32:1178–88.
34. Wenzel RG, Schwarz K, Padiyara RS. Topiramate for migraine prevention. Pharmacotherapy. 2006;26:375–87.
35. Margulis AV, Mitchell AA, Gilboa SM. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol. 2012;207:405.e1–7.
36. Van Issum C, Mavrakanas N, Schutz JS, Shaarawy T. Topiramate-induced acute bilateral angle closure and myopia: pathophysiology and treatment controversies. Eur J Ophthalmol. 2011;21:404–9.
37. Weissman NJ, Sanchez M, Koch GG, et al. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging. 2013;6:560–7.
38. Panchal HB, Patel P, Patel B, et al. Worsening of pre-existing valvulopathy with a new obesity drug lorcaserin, a selective 5-hydroxytryptamine 2c receptor agonist: a meta-analysis of randomized controlled trials [poster]. J Am Coll Cardiol. 2013;61(10):E1542.
39. Belviq (lorcaserin HCL) highlights of prescribing information. https://www.belviq.com/document/Belviq_Prescribing_information.pdf. Accessed 21 July 2014
40. Mark EJ, Patalas ED, Chang HT, et al. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med. 1997;337:602–6.
41. Kopelman P, Bryson A, Hickling R, et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond). 2007;31:494–9.
42. Kopelman P, Groot Gde H, Rissanen A, et al. Weight loss, HBA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring). 2010;18:108–15.
43. ® (generic name: cetilistat) tablets 120 mg in Japan for the treatment of obesity with complications. http://www.takeda.com/news/2013/20130920_5991.html. Accessed 21 July 2014
44. Greenway FL, Fujioka F, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595–605.
45. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19:110–20.
46. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21:935–43.
47. Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022–9.
48. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36:843–54.
49. Company announcement No 39/2013 – Novo Nordisk. http://www.novonordisk.com/include/asp/exe_news_attachment.asp?sAttachmentGUID=3f254ec7-lb91-4334-bf0d-572d4e6a4c3e. Accessed 21 July 2014
50. Wadden T, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37:1443–51.
51. Petrie JR. The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol. 2013;12:130.
52. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353:2111–20.
53. Garvey WT. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Expert Opin Drug Saf. 2013;12:741–56.
54. Hainer V, Toplak H, Mitrakou A. Treatment modalities of obesity: what fits whom? Diabetes Care. 2008;31(Suppl. 2):S269–77.
55. Liang BA, Mackey TK, Archer-Hayes N, Shinn LM. Illicit online marketing of lorcaserin before DEA scheduling. Obesity (Silver Spring). 2013;21:861–4.
56. Dvorak RV, Sharma AM, Astrup A. Antiobesity drugs: to be or not to be? Obes Rev. 2010;11:833–4.
57. Hainer V. How should the obese patient be managed? Possible approaches to a national obesity management network. Int J Obes Relat Metab Disord. 1999;23(Suppl. 4):S14–8.